DUBLIN, Oct. 30, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/8thxmj/tcell) has announced the addition of the "T-Cell Immunotherapy Market, 2015-2030" report to their offering.
This report provides an extensive study of the field of T-cell immunotherapy. With no marketed products, this emerging field is still in its infancy; the report provides a comprehensive view of the market segmented into the following three sub-groups: CAR-T therapies, TCR therapies and TIL therapies.
The market is characterised by a robust and opportunistic pipeline of products targeting both haematological cancers and solid tumours. As mentioned earlier, several research institutes have played a critical role in progression of the technology to its current stage. Post the initial research, industry players have collaborated with non-industry participants to fund the clinical and commercial development of these products.
Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis/University of Pennsylvania / The Children's Hospital of Philadelphia), JCAR017 (Juno Therapeutics / Seattle Children's Hospital), KTE-C19 and NY-ESO-1 TCR (Kite Pharma / National Cancer Institute), CD19-CAR (Takara Bio / Jichi Medical University) and LN-144 (Lion Biotechnologies / National Cancer Institute). Encouraging clinical results have accelerated the progress of these therapies as they have emerged as one of the most effective ways of leveraging the potential of immune system.
The market is also seeing a growing interest from several technology providers, especially those with capabilities in genome editing and viral and non-viral gene transfer. In addition, several T-cell immunotherapy companies and technology providers are also developing innovative safety switches to manage known side effects such as cytokine release syndrome and B-cell aplasia.
One of the key objectives of the study is to review and quantify the opportunities laid by the innovative programs of both small and big pharma firms. The unexploited and promising nature of this market supports the hopes pinned on multiple start-ups by several strategic investors and venture capital firms.
Amongst other elements, the report elaborates on the following key areas:
- The current state of the market with respect to key players, development stage of pipeline products (both clinical / preclinical) and targeted indications - Partnerships which have taken place in the recent past covering research and development collaborations, manufacturing agreements, license agreements specific to technology platforms, product co-development and co-commercialisation - Innovative technological platforms, such as safety switches, which have contributed significantly in overcoming the existing gaps in therapy regimen - Various investments and grants received by the companies focused in this area - Therapeutic areas forming the current focus of developers, the gradual drift and opportunity offered by non-oncological therapeutic areas - Competitive landscape, challenges and expected trend of market evolution within the three sub-segments - Development and sales potential based on target consumer segments, likely adoption rate and expected pricing
The research, analysis and insights presented in this report include potential sales of several CAR-T therapies, TCR therapies and TIL therapies; this analysis is backed by a deep understanding of key drivers behind the growth. With most products still in the early stage of development, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.
Companies Mentioned - Partial List of the 250+ Companies
- Cellular Therapeutics
- Celyad
- Children with Leukaemia
- Chinese PLA General Hospital
- City of Hope Medical Center
- CLL Global Research Foundation Alliance
- Cold Genesys
- Conkwest
- Cowen Investment
- CRISPR Therapeutics
- Fujita Health University
- GammaCell Biotechnologies
- Genentech
- Gilead Sciences
- GlaxoSmithKline
- Google Ventures
- Griffin Securities
- H. Lee Moffitt Cancer Center and Research Institute
- MaxCyte
- Mayo Clinic
- Medigene
- MolMed
- Monash University
- Morphotek
- Mustang Therapeutics
- Nagoya University
- Nantes University Hospital
- Nantworks
- National Cancer Institute
- National Institute of Health
- Peking University
- Perceptive Advisors
- Peter MacCallum Cancer Centre, University of Melbourne
- Quogue Capital
- QVT Financial
For more information visit http://www.researchandmarkets.com/research/8thxmj/tcell
Media Contact:
Laura Wood, +353-1-481-1716, press@researchandmarkets.net
Share this article